Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 11/20 | 0.54 |
| ▸ | CALCRL | Q16602 | 2/20 | 0.44 |
| ▸ | RAMP3 | O60896 | 5/20 | 0.42 |
| ▸ | CALCR | P30988 | 5/20 | 0.42 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29391817 | 0.87 | CAPN1 (0.44) | KEAP1CALCRLRAMP3CALCR | |
| SCHEMBL31433177 | 0.86 | KEAP1 (0.50) | KEAP1CALCRLRAMP3CALCR | |
| SCHEMBL30335608 | 0.86 | KEAP1 (0.49) | KEAP1CALCRLRAMP3CALCR | |
| SCHEMBL26186023 | 0.86 | KEAP1 (0.49) | KEAP1CALCRLRAMP3CALCR | |
| SCHEMBL26186082 | 0.86 | KEAP1 (0.49) | KEAP1CALCRLRAMP3CALCR | |
| SCHEMBL22342222 | 0.85 | KEAP1 (0.48) | KEAP1CXCR4 | |
| SCHEMBL30449622 | 0.82 | KEAP1 (0.48) | KEAP1CALCRLRAMP3CALCR | |
| SCHEMBL24834733 | 0.82 | KEAP1 (0.56) | KEAP1 | |
| SCHEMBL15819712 | 0.82 | KEAP1 (0.50) | KEAP1RAMP3CALCR | |
| SCHEMBL30997383 | 0.82 | RAMP3 (0.50) | KEAP1RAMP3CALCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200255478-A1 | NOVEL COMPOUNDS ACTIVATING THE NRF2 PATHWAY | ALMIRALL SA (ES) | 2020-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200255478-A1 | NOVEL COMPOUNDS ACTIVATING THE NRF2 PATHWAY | KEAP1, NFE2L2, HMOX1 | KEAP1 1/4885CALCRL 1421/4885RAMP3 2539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.